Is There a Role for Biosimilars in Value-Based Models?

Nov 24, 2019, 06:00 AM
As fee-for-service models give way to value-based healthcare delivery models, US providers and patients alike can hopefully forward to lower healthcare costs, increased quality of care, and improved outcomes. But what role will biosimilars have to play in value-based care? 

This week on the podcast, we're speaking with Jeffrey Scott MD, chief medical officer of Integra Connect, a company that uses cloud-based technologies and services that help specialty care providers optimize their performance in the ongoing shift to value-based models. Scott spoke with us about value-based contracting in the biosimilars context.